UNSPSC 51421603: Diflorasone

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28F2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T2DHJ9645W, chemically known as 6alpha-fluorobetamethasone-17,21 diacetate but generally known as diflorasone, which bears US NIH Compound Identifier 71414. European Medicines Agency schedules Diflorasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07126MIG.

UNSPSC 51421603 Diflorasone is a Commodity code that in recent state and local procurement practice captures pharmaceutical products and medical supplies used in community health and emergency response programs. The single recent opportunity shows state and local governments acquiring naloxone and drug deactivation systems for public health initiatives, though the code's nominal scope (diflorasone, a topical corticosteroid) does not align with the naloxone procurement posted under it. Issuing bodies under this code appear to include county health departments and community health agencies managing pharmaceutical inventory for emergency response and harm-reduction services.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The due date for bids was July 26, 2023, at 2:00 pm. Vendors must submit bids electronically, include all shipping and delivery costs, provide unit pricing for each line item, and comply with E-Verify requirements and drug-free workplace certification. The contract includes a two-year initial term with one-year renewal option and carries a three-month probationary period. The mismatch between the code's pharmaceutical name and the actual scope of the posted solicitation suggests this code receives limited relevant activity or that state procurement offices occasionally misclassify medical supply purchases; recent activity is too sparse to characterize geographic concentration or issuing-body patterns with confidence.